Evaxion Presents AI-Driven Polio Vaccine Concepts at World Vaccine Congress

Evaxion, a clinical-stage TechBio company, has developed novel AI-based polio vaccine design concepts in collaboration with the Gates Foundation. The concepts, including hybrid capsid designs and de novo designed B-cell antigen approaches, may be superior to current vaccines. Evaxion will present the data at the World Vaccine Congress. The company will also present data from its EVX-V1 vaccine program targeting cytomegalovirus.